Company
oricpharma
Our bold vision is to develop and commercialize innovative therapies that address cancer resistance, including by making existing therapies work better and longer.
Also known as ORIC Pharmaceuticals, ORIC Pharmaceuticals, Inc.
- Status
- IPOas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Founded
- 2014
- Legal name
- ORIC Pharmaceuticals, Inc.
- oricpharma.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
ORIC® is a science-driven, clinical stage company dedicated to developing novel therapies to improve patients’ lives by Overcoming Resistance In Cancer.
Funding snapshot
- Total raised
- $335MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $125M2025-05-29
Funding rounds
- Round, 2025
- $125M2025-05-29, SEC form D sold, 15 investors
- Round, 2024
- $125M2024-01-23, SEC form D sold, 10 investors
- Round, 2023
- $85M2023-06-27, SEC form D sold, 12 investors
About the company
- Status notes
- including its IPO in April 2020
Loading relationship preview